Diabetic dyslipidaemia in Kuwait

Medical Principles and Practice

Volumn 11, Issue SUPPL. 2, 2002, Pages 47-55

  Akanji, Abayomi O ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Coronary heart disease; Diabetes; Dyslipidaemia; Kuwait; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RESIN; SIMVASTATIN;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CONFERENCE PAPER; CORRELATION ANALYSIS; DIABETIC DIET; DIET SUPPLEMENTATION; DYSLIPIDEMIA; EXERCISE; GLUCOSE INTAKE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; KUWAIT; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; SECONDARY PREVENTION;

CLINICAL TRIALS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; KUWAIT; MALE; PREVALENCE; RISK FACTORS;

EID: 0036436830     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066409     Document Type: Conference Paper

References (44)

1. Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M: Non-insulin dependent diabetes in Kuwait: Prevalence rates and associated risk factors. Diab Res Clin Pract 1998;42: 187-196.
2. Akanji AO, Al-Sulaiman AS, Prabha K, Tahzeeb S: A lipid clinic service in Kuwait: Preliminary observations. Med Principles Pract 1996;5:151-159.
3. Akanji AO, Al-Sulaiman A, Kinatamitath P, Safar S, Al-Zaid K, Mojimiyi OA: Profile of hyperlipidaemic patients in Kuwait: Frequency of cardiovascular disease risk factors at presentation and initial response to treatment. J Kuwait Med Assoc 1997;29:25-33.
4. Haffner SM: Coronary heart disease in patients with diabetes. N Engl J Med 2000;342:1040-1042.
5. Syvanne M, Taskinen M-R: Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet 1997;350(suppl 1):20-23.
6. Nathan DM, Meigs J, Singer DE: The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is... or is it? Lancet 1997;350(suppl 1):4-9.
7. Alwan AA: Cardiovascular diseases in the eastern Mediterranean region. World Hlth Stat Q 1993;46:97-100.
8. Radovanovic Z: Mortality patterns in Kuwait: Inferences from death certificate data. Eur J Epidemiol 1994;10:733-736.
9. Ministry of Health, Kuwait: Vital and Health Statistics Abstract 1994. Department of Statistics and Medical Records, Health & Vital Statistics Division, 1994.
10. Rashed W, Zubaid M, Singh S, Memon A: Gender Differences in Thrombolytic Therapy use and In-hospital Mortality after Acute Myocardial Infarction in a Kuwaiti Population. Proceedings, Kuwait University Health Sciences Poster Day, April 1998, p 34.
11. Al-Owaish RA: Descriptive epidemiology of AMI in Kuwait, 1978. Bull WHO 1983;61:509-516.
12. Al-Adsani A, Memon A, Peneva A, Baidas G: Clinical epidemiology of acute myocardial infarction in Kuwait. Acta Cardiol 2000;55:17-23.
13. Lauer MS, Fontanarosa PB: Updated guidelines for cholesterol management. JAMA 2001;285:2508-2509.
14. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
15. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
16. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
17. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;4:614-620.
18. Haffner SM: The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic patients: Implications for the prevention of coronary heart disease. Diabetes Care 1997;4:469-471.
19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E: The Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
20. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
21. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with Pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-1307.
22. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr, for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-1622.
23. Brown WV: Lipoprotein disorders in diabetes mellitus. Med Clin N Am 1994;78:143-161.
24. Jenkins AJ, Best JD: The role of lipoprotein(a) in the vascular complications of diabetes mellitus. J Intern Med 1995;237:359-365.
25. Akanji AO: The relationships between plasma lipoproteins and apolipoprotein A-1 and B levels in hyperlipidaemic patients in Kuwait. J Kuwait Med Assoc 1997;29:418-422.
26. Akanji AO, Abdullah A, Tahzeeb S: Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait. Eur J Clin Invest 1997;27:380-386.
27. Akanji AO, Al-Shayji IAR, Kumar P: Metabolic and anthropometric determinants of serum Lp(a) concentrations and apo(a) polymorphism in a healthy Arab population. Int J Obes 1999;23:855-862.
28. Abdella NA, Mojiminiyi OA, Akanji AO, Al Mohammadi H, Moussa MA: Serum lipoprotein (a) concentration as a cardiovascular risk factor in Kuwaiti type 2 diabetic patients. J Diab Compl 2001;15:270-276.
29. Akanji AO: Apo(a) isoforms do not predict coronary heart disease risk in a Gulf Arab population. Ann Clin Biochem 2000;37:360-366.
30. Stehouwer CDA, Schaper NC: The pathogenesis of vascular complications of diabetes mellitus: One voice or many? Eur J Clin Invest 1996;26:535-543.
31. Graier WF, Kostner GM: Glycated low density lipoprotein and atherogenesis: The missing link between diabetes mellitus and hypercholesterolaemia. Eur J Clin Invest 1997;27:457-459.
32. Kramer-Guth A, Quaschning T, Galle J, Baumstark MW, Nauck M, Schollmeyer P, Marz W, Wanner C: Structural and compositional modifications of diabetic low density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur J Clin Invest 1997;27:460-468.
33. Pentikainen MO, Oorni K, Ala-Korpela M, Kovanen PT: Modified LDL - Trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med 2000;247:359-370.
34. Akanji AO, Al-Shayji I: The relationships between insulin and plasminogen activator inhibitor 1 levels: Assessment in groups of subjects with dyslipidaemia and hypertension. Clin Chim Acta 1998;274:41-52.
35. Abdella N, Akanji AO, Moussa M, Al Assoussi A: Relation of serum sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti Type 2 diabetic patients. Diab Res Clin Pract 2000;50:65-72.
36. Lindberg G, Eklund GA, Gulberg B, Rastam L: Serum sialic acid concentration and cardiovascular mortality. BMJ 1991;302:143-146.
37. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
38. Dean JD, Durrington PN: Treatment of dyslipoproteinaemia in diabetes mellitus. Diab Med 1996;13:297-312.
39. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998;21:179-182.
40. Weissberg PL: Atherogenesis: Current understanding of the causes of atheroma. Heart 2000;83:247-252.
41. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 2002;346:393-403.
42. Akanji AO, Mojiminiyi OA, Abdella N: Beneficial changes in serum Apo A-1 and its ratio to Apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait. Eur J Clin Nutr 2000;54:508-513.
43. NIH Technology Assessment Panel: Methods for voluntary weight loss and control. Ann Intern Med 1992;116:942-949.
44. Zimmet P, Collins VR, Dowse GR, Alberti KGMM, Gareeboo H, Chitson P: The relationship of physical activity to cardiovascular risk factors in Mauritians. Am J Epidemiol 1991; 134:862-875.